SQ 2201
Alternative Names: SQ-2201; SQP22+SQT01Latest Information Update: 19 Jun 2024
At a glance
- Originator Shasqi
- Class Antineoplastics; Auristatins; Drug conjugates; Fab fragments; Immunotoxins
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 05 Apr 2024 Efficacy and adverse events data from a preclinical trial in Solid tumour presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 05 Apr 2024 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 28 Jun 2023 Preclinical trials in Solid tumours in USA (Intratumoural), prior to June 2023